Compositions and methods for therapeutic delivery with frozen particles

• US 9,072,688 B2
• Filed: 10/31/2008
• Issued: 07/07/2015
• Est. Priority Date: 10/31/2008
• Status: Active Grant

• Current Assignee: Gearbox LLC (Intellectual Ventures LLC)
• Original Assignee: The Invention Science Fund I, L.L.C. (Intellectual Ventures LLC)
• Inventors: Boyden, Edward S., Hyde, Roderick A., Leuthardt, Eric C., Myhrvold, Nathan P., Sweeney, Elizabeth A., Wood, Lowell L. Jr.
• Primary Examiner(s): Hartley, Michael G
• Assistant Examiner(s): Rider, Lance W
• Application Number:
  US12/290,671
• Publication Number:
  US 20100111842A1
• Time in Patent Office: 2,440 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 41/0004 Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 51/1244 microparticles or nanoparticles, e.g. polymeric nanoparticles
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/007 Pulmonary tract; Aromatherapy
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61K 9/1611 Inorganic compounds
• CPC Class Codes: A61K 9/1641 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
• CPC Class Codes: A61K 9/1664 Compounds of unknown constitution, e.g. material from plants or animals oils, fats, waxes, shellac A61K9/1617
• CPC Class Codes: A61K 9/1688 resulting in pure drug agglomerate optionally containing up to 5% of excipient
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00

Abstract

Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Claims

1. A therapeutic composition, comprising:

one or more frozen hydrogen oxide particles less than 200 micrometers in size and coated with a specific cell receptor;

the one or more frozen hydrogen oxide particles each further defining at least two cavities, the first cavity containing at least one anti-tumor agent, including at least one of an alkylating agent, antimetabolite, anthracycline, plant alkaloid, topoisomerase inhibitor, monoclonal antibody, or tyrosine kinase inhibitor;

and the second cavity containing one or more of a cytokine, chemokine, anti-angiogenic factor, anti-inflammatory agent, vaccine, hormone, or radioactive agent.

2. The therapeutic composition of claim 1, wherein the one or more frozen hydrogen oxide particles are in phase ice Ic.

3. The therapeutic composition of claim 1, wherein the composition has a density greater than approximately 0.92 g/cm³.

4. The therapeutic composition of claim 1, wherein the one or more frozen hydrogen oxide particles exist at about −

20°

C., about −

30°

C., about −

40°

C., about −

50°

C., about −

60°

C., about −

70°

C., about −

75°

C., about −

80°

C., about −

85°

C., about −

90°

C., about −

95°

C., about −

100°

C., about −

120°

C., about −

150°

C., about −

180°

C., about −

200°

C., about −

220°

C., about −

250°

C., or any value less than or therebetween.

5. The therapeutic composition of claim 1, wherein the at least one major dimension includes at least one of the radius, diameter, length, width, height, or perimeter.

6. The therapeutic composition of claim 1, wherein the at least one plant alkaloid includes paclitaxel.

7. The therapeutic composition of claim 1, further including one or more of nitrogen, oxygen, air, helium, neon, argon, xenon, chlorine, bromine, or carbon dioxide, polyethylene glycol, acetone, ethyl acetate, dimethyl sulfoxide, dimethyl formamide, dioxane, hexamethylphosphorotriamide, perfluorohydrocarbon, methanol, ethanol, tert-butyl alcohol, formic acid, hydrogen fluoride, ammonia, acetic acid, benzene, carbon tetrachloride, acetonitrile, hexane, methylene chloride, carboxylic acid, saline, Ringer'"'"'s solution, lactated Ringer'"'"'s solution, Hartmann'"'"'s solution, acetated Ringer'"'"'s solution, phosphate buffered solution, TRIS-buffered saline solution, Hank'"'"'s balanced salt solution, Earle'"'"'s balanced salt solution, standard saline citrate, HEPES-buffered saline, dextrose, glucose, or diethyl ether.

8. The therapeutic composition of claim 1, wherein the one or more frozen hydrogen oxide particles approximate the shape of at least one of a sphere, bullet, flechette, cone, needle, arrow, spear, diamond, pyramid, cylinder, minie ball, shuttlecock, spiral, bell, pear, crystal, cube, spheroid, tetrahedron, or crescent.

9. The therapeutic composition of claim 1, wherein the one or more frozen particles include a plurality of frozen particles that are approximately uniform in size, shape, weight, or density.

10. The therapeutic composition of claim 1, wherein the therapeutic composition includes one or more of a suspension, mixture, solution, sol, clathrate, colloid, emulsion, microemulsion, aerosol, ointment, capsule, powder, tablet, suppository, cream, device, paste, liniment, lotion, ampule, elixir, spray, suspension, syrup, tincture, detection material, polymer, biopolymer, buffer, adjuvant, diluent, lubricant, disintegration agent, suspending agent, solvent, light-emitting agent, colorimetric agent, glidant, anti-adherent, anti-static agent, surfactant, plasticizer, emulsifying agent, flavor, gum, sweetener, coating, binder, filler, compression aid, encapsulation aid, preservative, granulation agent, spheronization agent, stabilizer, adhesive, pigment, sorbent, nanoparticle, or gel.

11. The therapeutic composition of claim 1, further including one or more reinforcement agents.

12. The therapeutic composition of claim 11, wherein the one or more reinforcement agents include at least one of a natural, artificial, or synthetic agent.

13. The therapeutic composition of claim 11, wherein the one or more reinforcement agents include at least one of a plate, fiber, or spheroid.

14. The therapeutic composition of claim 11, wherein the one or more reinforcement agents include one or more of polyaramid, vinylester matrix, metal, ceramic, fiberglass, cellulose, broad carbide, aromatic polyamide, nylon, silk, rayon, acetate, modacrylic, olefin, acrylic, polyester, aromatic polyester, poly-lactic acid, vinyon, saran, spandex, vinalon, aromatic nylon, vinylidene chloride, modal, polybenzimidazole, sulfur, lyocell, orlon, zylon, high-performance polyethylene, polypyridobenzimidazole, vectran, acrylonitrile rubber, glass, copper, iron, steel, sodium, potassium, calcium, zinc, manganese, carbon, magnesium, silicon, silica, plant matter, animal matter, or mineral matter.

15. The therapeutic composition of claim 11, wherein the one or more reinforcement agents are located at least on the surface or beneath the surface of the particle.

16. The therapeutic composition of claim 11, wherein the one or more reinforcement agents are located within the particle.

17. The therapeutic composition of claim 1, further including at least one of a polymer, biopolymer, nanoparticle, or detection material.

18. The therapeutic composition of claim 17, wherein the detection material includes at least one electronic identification device.

19. The therapeutic composition of claim 18, wherein the at least one electronic identification device includes at least one radio frequency identification device.

20. The therapeutic composition of claim 17, wherein the detection material includes at least one radioactive element.

21. The therapeutic composition of claim 20, wherein the at least one radioactive element includes one or more of ³²P, ³⁵S, ¹³C, ¹³¹I, ¹⁹¹Ir, ¹⁹²Ir, ¹⁹³Ir, ²⁰¹Tl, or ³H.

22. The therapeutic composition of claim 17, wherein the detection material includes at least one colorimetric substance.

23. The therapeutic composition of claim 22, wherein the at least one colorimetric substance includes one or more of an inorganic, organic, biological, natural, artificial, or synthetic substance.

24. The therapeutic composition of claim 22, wherein the at least one colorimetric substance includes one or more of a dye, pigment, or light-emitting substance.

25. The therapeutic composition of claim 24, wherein the light-emitting substance includes at least one of a fluorescent substance, phosphorescent substance, or quantum dot.

26. The therapeutic composition of claim 22, wherein the at least one colorimetric substance is biocompatible.

27. The therapeutic composition of claim 17, wherein the detection material includes at least one of a diamagnetic particle, ferromagnetic particle, paramagnetic particle, super paramagnetic contrast agent, or other magnetic particle.

28. The therapeutic composition of claim 1, formulated to be administered by one or more of topical delivery, oral delivery, enteral delivery, mucosal delivery, percutaneous delivery, or parenteral delivery.

29. The therapeutic composition of claim 28, wherein parenteral delivery includes at least one of intravenous delivery, intra-arterial delivery, intracardiac delivery, subcutaneous delivery, intraperitoneal delivery, or intramuscular delivery.

30. The therapeutic composition of claim 1, formulated to be administered by high velocity impact.

31. The therapeutic composition of claim 1, formulated to be administered by one or more devices.

32. The therapeutic composition of claim 1, further including at least one pharmaceutically-acceptable carrier or excipient.

33. The therapeutic composition of claim 1, further including one or more explosive materials.